12/2/2011

The FDA, through the President's Emergency Plan for AIDS Relief, tentatively authorized Mylan's second-line HIV therapy comprising ritonavir and atazanavir sulfate. The ingredients are generic forms of Abbott Laboratories' Norvir and Bristol-Myers Squibb's Reyataz, respectively.

Full Story:
Reuters

Related Summaries